F. Xiao, I. Fofana, and C. Thumann, Synergy of entry inhibitors with direct-acting 1042 antivirals uncovers novel combinations for prevention and treatment of hepatitis C, Gut, vol.1043, pp.483-94, 2015.

C. C. Colpitts, R. G. Tawar, and L. Mailly, Humanisation of a claudin-1-specific 1045 monoclonal antibody for clinical prevention and cure of HCV infection without escape, Gut, vol.1046, p.2017

M. Fukasawa, S. Nagase, and Y. Shirasago, Monoclonal antibodies against 1048 extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model, J Virol, vol.1049, pp.4866-79, 2015.

I. Hotzel, V. Chiang, and J. Diao, Efficient production of antibodies against a 1051 mammalian integral membrane protein by phage display, Protein Eng Des Sel, vol.24, pp.679-1052, 2011.

R. Paciello, R. A. Urbanowicz, and G. Riccio, Novel human anti-claudin 1 mAbs inhibit 1054

, hepatitis C virus infection and may synergize with anti-SRB1 mAb, J Gen Virol, vol.97, pp.82-1055, 2016.

I. Fofana, S. Fafi-kremer, and P. Carolla, Mutations that alter use of hepatitis C virus 1057 cell entry factors mediate escape from neutralizing antibodies, Gastroenterology, vol.1058, pp.223-256, 2012.

K. Okai, N. Ichikawa-tomikawa, and A. C. Saito, A novel occludin-targeting monoclonal 1060 antibody prevents hepatitis C virus infection in vitro, Oncotarget, vol.9, pp.16588-98, 2018.

M. L. Michta, S. E. Hopcraft, and C. M. Narbus, Species-specific regions of occludin 1062 required by hepatitis C virus for cell entry, J Virol, vol.84, pp.11696-708, 2010.

D. J. Felmlee, A. Coilly, and R. T. Chung, New perspectives for preventing hepatitis C 1064 virus liver graft infection, Lancet Infect Dis, vol.16, pp.735-780, 2016.

C. C. Colpitts, R. T. Chung, and T. F. Baumert, Entry Inhibitors: A Perspective for Prevention of 1066

, Hepatitis C Virus Infection in Organ Transplantation, ACS Infect Dis, vol.3, pp.620-623, 2017.

A. M. Rosager, M. D. Sorensen, and R. H. Dahlrot, Expression and prognostic value of 1068 JAM-A in gliomas, J Neurooncol, vol.135, pp.107-124, 2017.

S. Hao, Y. Yang, and Y. Liu, JAM-C promotes lymphangiogenesis and nodal 1097 metastasis in non-small cell lung cancer, Tumour Biol, vol.35, pp.5675-87, 2014.

M. L. Arcangeli, V. Frontera, and F. Bardin, The Junctional Adhesion Molecule-B 1099 regulates JAM-C-dependent melanoma cell metastasis, FEBS Lett, vol.586, pp.4046-51, 2012.

S. Ghislin, D. Obino, and S. Middendorp, Junctional adhesion molecules are required 1101 for melanoma cell lines transendothelial migration in vitro, Pigment Cell Melanoma Res, vol.1102, pp.504-515, 2011.

H. F. Langer, V. V. Orlova, and C. Xie, A novel function of junctional adhesion molecule1104 C in mediating melanoma cell metastasis, Cancer Res, vol.71, pp.4096-105, 2011.

D. A. Leinster, B. Colom, and J. R. Whiteford, Endothelial cell junctional adhesion 1106 molecule C plays a key role in the development of tumors in a murine model of ovarian 1107 cancer, FASEB J, vol.27, pp.4244-53, 2013.

Y. Zhang, F. Xia, and X. Liu, JAM3 maintains leukemia-initiating cell self-renewal 1109 through LRP5/AKT/beta-catenin/CCND1 signaling, J Clin Invest, vol.128, pp.1737-51, 2018.

K. Ebnet, Junctional Adhesion Molecules (JAMs): Cell Adhesion Receptors With 1111

, Pleiotropic Functions in Cell Physiology and Development, Physiol Rev, vol.97, pp.1529-54, 2017.

T. A. Martin, G. Watkins, and W. G. Jiang, The Coxsackie-adenovirus receptor has elevated 1113 expression in human breast cancer, Clin Exp Med, vol.5, pp.122-130, 2005.

A. Bruning, E. Stickeler, and D. Diederich, Coxsackie and adenovirus receptor 1115 promotes adenocarcinoma cell survival and is expressionally activated after transition from 1116 preneoplastic precursor lesions to invasive adenocarcinomas, Clin Cancer Res, vol.1117, pp.4316-4336, 2005.

C. T. Giaginis, A. C. Zarros, and M. A. Papaefthymiou, Coxsackievirus and adenovirus 1119 receptor expression in human endometrial adenocarcinoma: possible clinical implications

, World J Surg Oncol, vol.6, p.59, 2008.

Z. Chen, Q. Wang, and J. Sun, Expression of the coxsackie and adenovirus receptor 1122 in human lung cancers, Tumour Biol, vol.34, pp.17-24, 2013.

K. Saito, M. Sakaguchi, and H. Iioka, Coxsackie and adenovirus receptor is a critical 1124 regulator for the survival and growth of oral squamous carcinoma cells, Oncogene, vol.1125, pp.1274-86, 2014.

D. Reimer, I. Steppan, and A. Wiedemair, Soluble isoforms but not the transmembrane 1127 form of coxsackie-adenovirus receptor are of clinical relevance in epithelial ovarian cancer

, Int J Cancer, vol.120, pp.2568-75, 2007.

C. Giaginis, A. Zarros, and P. Alexandrou, Evaluation of coxsackievirus and 1130 adenovirus receptor expression in human benign and malignant thyroid lesions, APMIS, vol.1131, pp.210-231, 2010.

D. Vindrieux, L. Corre, L. Hsieh, and J. T. , Coxsackie and adenovirus receptor is a 1133 target and a mediator of estrogen action in breast cancer, Endocr Relat Cancer, vol.18, pp.311-1134, 2011.

Y. Maekawa, M. Ouzounian, and M. A. Opavsky, Connecting the missing link between 1136 dilated cardiomyopathy and viral myocarditis: virus, cytoskeleton, and innate immunity, Circulation, vol.115, pp.5-8, 1137.

A. O. Leech, R. G. Cruz, and A. D. Hill, Paradigms lost-an emerging role for over1139 expression of tight junction adhesion proteins in cancer pathogenesis, Ann Transl Med, vol.1140, p.184, 2015.

S. S. Oliveira and J. A. Morgado-diaz, Claudins: multifunctional players in epithelial tight 1142 junctions and their role in cancer, Cell Mol Life Sci, vol.64, pp.17-28, 2007.

M. Itoh and M. J. Bissell, The organization of tight junctions in epithelia: implications for 1144 mammary gland biology and breast tumorigenesis, J Mammary Gland Biol Neoplasia, vol.1145, pp.449-62, 2003.

H. Akasaka, F. Sato, and S. Morohashi, Anti-apoptotic effect of claudin-1 in tamoxifen1147 treated human breast cancer MCF-7 cells, BMC Cancer, vol.10, p.548, 2010.

Y. Liu, L. Wang, and X. Y. Lin, Anti-apoptotic effect of claudin-1 on TNF-alpha-induced 1149 apoptosis in human breast cancer MCF-7 cells, Tumour Biol, vol.33, pp.2307-2322, 2012.

C. Achari, S. Winslow, and C. Larsson, Down Regulation of CLDND1 Induces Apoptosis in 1151

, Breast Cancer Cells. PLoS One, vol.10, p.130300, 2015.

J. W. Lee, S. J. Lee, and J. Seo, Increased expressions of claudin-1 and claudin-7 during 1153 the progression of cervical neoplasia, Gynecol Oncol, vol.97, pp.53-62, 2005.

T. Kinugasa, Q. Huo, and D. Higashi, Selective up-regulation of claudin-1 and claudin1155 2 in colorectal cancer, Anticancer Res, vol.27, pp.3729-3763, 2007.

M. Caruso, K. Y. Fung, and J. Moore, Claudin-1 Expression Is Elevated in Colorectal 1157

, Cancer Precursor Lesions Harboring the BRAF V600E Mutation, Transl Oncol, vol.7, pp.456-1158, 2014.

Q. Huo, T. Kinugasa, and L. Wang, Claudin-1 protein is a major factor involved in the 1160 tumorigenesis of colorectal cancer, Anticancer Res, vol.29, pp.851-858, 2009.

M. B. Resnick, T. Konkin, and J. Routhier, Claudin-1 is a strong prognostic indicator in 1162 stage II colonic cancer: a tissue microarray study, Mod Pathol, vol.18, pp.511-519, 2005.

A. B. Singh, A. Sharma, and P. Dhawan, Claudin-1 expression confers resistance to anoikis 1164 in colon cancer cells in a Src-dependent manner, Carcinogenesis, vol.33, pp.2538-2585, 2012.

G. M. Sheehan, B. V. Kallakury, and C. E. Sheehan, Loss of claudins-1 and-7 and 1166 expression of claudins-3 and-4 correlate with prognostic variables in prostatic 1167 adenocarcinomas, Hum Pathol, vol.38, pp.564-573, 2007.

V. N. Tzelepi, A. C. Tsamandas, and H. D. Vlotinou, Tight junctions in thyroid 1169 carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid 1170 neoplasms, Mod Pathol, vol.21, pp.22-30, 2008.

J. Lv, B. Sun, and Z. Mai, CLDN-1 promoted the epithelial to migration and 1172 mesenchymal transition (EMT) in human bronchial epithelial cells via Notch pathway, 1173.

, Cell Biochem, vol.432, pp.91-99, 2017.

N. Miwa, M. Furuse, and S. Tsukita, Involvement of claudin-1 in the beta-catenin/Tcf 1175 signaling pathway and its frequent upregulation in human colorectal cancers, Oncol Res, vol.1176, pp.469-76, 2001.

L. Gonzalez-mariscal, R. Tapia, and D. Chamorro, Crosstalk of tight junction components 1178 with signaling pathways, Biochim Biophys Acta, vol.1778, pp.729-56, 2008.

S. Tabaries, Z. Dong, and M. G. Annis, Claudin-2 is selectively enriched in and 1180 promotes the formation of breast cancer liver metastases through engagement of integrin 1181 complexes, Oncogene, vol.30, pp.1318-1346, 2011.

S. Kimbung, A. Kovacs, and P. O. Bendahl, Claudin-2 is an independent negative 1183 prognostic factor in breast cancer and specifically predicts early liver recurrences, Mol Oncol, vol.1184, pp.119-147, 2014.

S. Tabaries, M. G. Annis, and B. E. Hsu, Lyn modulates Claudin-2 expression and is a 1186 therapeutic target for breast cancer liver metastasis, Oncotarget, vol.6, pp.9476-87, 2015.

S. Tabaries, F. Dupuy, and Z. Dong, Claudin-2 promotes breast cancer liver 1188 metastasis by facilitating tumor cell interactions with hepatocytes, Mol Cell Biol, vol.1189, pp.2979-91, 2012.

M. Buchert, M. Papin, and C. Bonnans, Symplekin promotes tumorigenicity by up1191 regulating claudin-2 expression, Proc Natl Acad Sci U S A, vol.107, pp.2628-2661, 2010.

A. Ikari, T. Sato, and R. Watanabe, Increase in claudin-2 expression by an

E. Mek, /ERK/c-Fos pathway in lung adenocarcinoma A549 cells, Biochim Biophys Acta, vol.1194, pp.1110-1118, 2012.

A. Ikari, R. Watanabe, and T. Sato, Nuclear distribution of claudin-2 increases cell 1196 proliferation in human lung adenocarcinoma cells, Biochim Biophys Acta, vol.1843, pp.2079-88, 2014.

H. R. Hintsala, M. Siponen, and K. M. Haapasaari, Claudins 1, 2, 3, 4, 5 and 7 in solar 1198 keratosis and squamocellular carcinoma of the skin, Int J Clin Exp Pathol, vol.6, pp.2855-63, 2013.

S. Zeissig, N. Burgel, and D. Gunzel, Changes in expression and distribution of 1200 claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active 1201

, Crohn's disease, Gut, vol.56, pp.61-72, 2007.

N. Burgel, C. Bojarski, and J. Mankertz, Mechanisms of diarrhea in collagenous colitis

, Gastroenterology, vol.123, pp.433-476, 2002.

K. J. Hewitt, R. Agarwal, and P. J. Morin, The claudin gene family: expression in normal and 1205 neoplastic tissues, BMC Cancer, vol.6, p.186, 2006.

P. Kolokytha, P. Yiannou, and D. Keramopoulos, Claudin-3 and claudin-4: distinct 1207 prognostic significance in triple-negative and luminal breast cancer, Appl Immunohistochem, p.1208

, Mol Morphol, vol.22, pp.125-156, 2014.

W. F. Souza, N. Fortunato-miranda, and B. K. Robbs, Claudin-3 overexpression 1210 increases the malignant potential of colorectal cancer cells: roles of ERK1/2 and PI3K-Akt as 1211 modulators of EGFR signaling, PLoS One, vol.8, p.74994, 2013.

G. E. Konecny, R. Agarwal, and G. A. Keeney, Claudin-3 and claudin-4 expression in 1213 serous papillary, clear-cell, and endometrioid endometrial cancer, Gynecol Oncol, vol.1214, pp.263-272, 2008.

A. D. Santin, S. Bellone, and M. Marizzoni,

, receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy 1217 using Clostridium perfringens enterotoxin (CPE), Cancer, vol.109, pp.1312-1334, 2007.

S. Satake, S. Semba, and Y. Matsuda, Cdx2 transcription factor regulates claudin-3

, and claudin-4 expression during intestinal differentiation of gastric carcinoma, Pathol Int, vol.1220, pp.156-63, 2008.

Y. L. Choi, J. Kim, and M. J. Kwon, Expression profile of tight junction protein claudin 3 1222 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol, Histopathol, vol.22, pp.1185-95, 1223.

J. Luettig, R. Rosenthal, and C. Barmeyer, Claudin-2 as a mediator of leaky gut barrier 1225 during intestinal inflammation, Tissue Barriers, vol.3, p.977176, 2015.

B. A. Mcclane, The complex interactions between Clostridium perfringens enterotoxin 1227 and epithelial tight junctions, Toxicon, vol.39, pp.1781-91, 2001.

D. Suren, M. Yildirim, and V. Kaya, Expression patterns of claudins 1, 4, and 7 and 1229 their prognostic significance in nasopharyngeal carcinoma, J BUON, vol.20, pp.212-219, 2015.

X. Y. Pan, B. Wang, and Y. C. Che, Expression of claudin-3 and claudin-4 in normal, p.1231

, hyperplastic, and malignant endometrial tissue, Int J Gynecol Cancer, vol.17, pp.233-274, 2007.

A. B. Singh, A. Sharma, and P. Dhawan, Claudin family of proteins and cancer: an overview

, J Oncol, p.541957, 2010.

R. Philip, S. Heiler, and W. Mu, Claudin-7 promotes the epithelial-mesenchymal 1235 transition in human colorectal cancer, Oncotarget, vol.6, pp.2046-63, 2015.

S. J. Kuo, S. Y. Chien, and C. Lin, Significant elevation of CLDN16 and HAPLN3 gene 1237 expression in human breast cancer, Oncol Rep, vol.24, pp.759-66, 2010.

L. B. Rangel, C. A. Sherman-baust, and R. P. Wernyj, Characterization of novel human 1239 ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression

, Oncogene, vol.22, pp.7225-7257, 2003.

W. Men, T. A. Martin, and F. Ruge, Expression of claudins in human clear cell renal cell 1242 carcinoma, Cancer Genomics Proteomics, vol.12, pp.1-8, 2015.

D. B. Simon, Y. Lu, and K. A. Choate, Paracellin-1, a renal tight junction protein required 1244 for paracellular Mg2+ resorption, Science, vol.285, pp.103-109, 1999.

T. A. Martin, J. Lane, and H. Ozupek, Claudin-20 promotes an aggressive phenotype in 1246 human breast cancer cells, Tissue Barriers, vol.1, p.26518, 2013.

C. Forster, T. Kahles, and S. Kietz, Dexamethasone induces the expression of 1248 metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND

, J Physiol, vol.580, pp.937-986, 2007.

E. A. Felinski and D. A. Antonetti, Glucocorticoid regulation of endothelial cell tight junction 1251 gene expression: novel treatments for diabetic retinopathy, Curr Eye Res, vol.30, pp.949-57, 2005.

M. Kato-nakano, M. Suzuki, and S. Kawamoto, Characterization and evaluation of the 1253 antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4

, Anticancer Res, vol.30, pp.4555-62, 2010.

X. Li, M. Iida, and M. Tada, Development of an anti-claudin-3 and-4 bispecific 1256 monoclonal antibody for cancer diagnosis and therapy, J Pharmacol Exp Ther, vol.351, pp.206-1257, 2014.

M. Suzuki, M. Kato-nakano, and S. Kawamoto, Therapeutic antitumor efficacy of 1259 monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers, Cancer Sci, vol.1260, pp.1623-1653, 2009.

, TJ proteins involved in 1310 the HCV entry process are depicted in black, non-TJ host entry factors are depicted in white, HCV infection increases CLDN1 expression